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LEARNING OBJECTIVES
1. The difference between self-assembled and
polymerized and the ramification in a wound.
2. How does the body react to non-assembled peptides
and assembled peptide materials? Where do they go?
3. How these nano materials mimic how the body
develops, stops bleeding and allows for healing.
CME QUESTIONS
1. Will self-assembled peptides cause an immune
response?
2. How do self-assembled peptide materials differ from
polymerized materials? Can self-assembled peptides
also polymerize?
3. How does pH affect the local environment? What









The intersection of nanotechnology and healthcare is
rapidly taking center stage and the fruits of this marriage
are on the visible horizon. While nano biomedicine has led
to wildly futuristic promises, it has also presented real
breakthroughs in drug research, development and
formulation, as well as in the field of diagnostics. Two
very different breakthroughs are explored: (1) the use of
nanotechnology to repair the brain and show return of
function; (2) the creation of a nano hemostatic agent that
promptly stops bleeding, while also providing a clear
visual operating field during surgery. Both developments
represent significant nanobiomedical advances that hold
great promise in treating human conditions in the
foreseeable future. 
There are several formidable barriers that must be
overcome to achieve axonal regeneration after injury in
the central nervous system (CNS), whether caused by a
knife or a stroke. These obstacles are: (1) scar tissue
formation after tissue injury; (2) gaps in nervous tissue
formed during phagocytosis of dying cells after injury; 
(3) factors that inhibit axon growth in the mature
mammalian CNS; and (4) failure of many adult neurons to
initiate axonal extension. 
We are now able to demonstrate the creation of a
permissive environment for axonal regrowth using a
synthetic biological nanomaterial that self assembles in
vivo, with components that break down into beneficial
building blocks and produce no adverse effects on the
CNS. This discovery, by reducing or overcoming the first
two obstacles and possibly more, allows for the




The previously undiscovered treatment in this study used
a designed self-assembling peptide that spontaneously
forms nanofibers, creating a scaffold-like tissue-bridging
structure that we found to provide a framework for partial
reinnervation by axons with regenerative potential in
young and adult animals. Because the peptide fibers are
nanoscale, there is likely a direct interaction between the
peptide scaffold, the extracellular matrix, and the neural
tissue on both sides of the lesion. These structures create
a scaffold that connects the two faces of the lesion,
allowing movement of cells into the scaffold. The peptide
scaffold in our experiments created a permissive
environment for axonal growth while discouraging or
preventing the scar formation that normally occurs at an
early stage. This material appears to offer a treatment for
ameliorating or bypassing tissue disruptions after
neuronal damage. 
SAPNSs are synthetic biological materials formed through
the assembly of ionic self-complementary peptides and
are designed by using alternating positive and negative 
L-amino acids that form highly hydrated scaffolds in the
presence of physiological-concentration salts, i.e., saline,
tissue culture media, physiological solutions, or human
body fluids such as cerebrospinal fluid. The scaffold
consists of β-sheet ionic peptide containing 50% charged
residues. A number of additional self-assembling peptides
have been designed, synthesized, and characterized for
salt-facilitated matrix formation. The SAPNS consists of
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interwoven nanofibers, and the individual fibers are 10 nm
in diameter1.
NANOFIBER DENSITY CORRELATES WITH PEPTIDE
SOLUTION CONCENTRATION
This designed peptide nanofiber scaffold provides several
benefits over currently available polymer biomaterials: (1)
The peptide scaffold forms a network of nanofibers that
are similar in scale to the native extracellular matrix and
therefore provides an in vivo environment for cell growth,
migration, and differentiation; (2) it can be broken down
into natural L-amino acids and potentially used by the
surrounding tissue, because the majority of the material is
excreted in the urine; (3) it is synthetic and free of
chemical and biological contaminants that typically are
present in animal-derived biomaterials such as many
collagens; and (4) it appears to be immunologically inert,
thus avoiding the problem of neural tissue rejection1. 
All of these attributes make it very attractive for using the
peptide nanofiber scaffold in both in vitro and in vivo
studies. Our previous studies show that the SAPNS can
support the attachment of a variety of mammalian primary
cells in tissue culture. Additionally, one of the peptide
scaffolds, arginine, alanine, aspartate, and alanine
(RADA)16-I supports not only the growth of PC12 cells but
also the formation of functional synapses in vitro using rat
primary hippocampal neurons. Thus, RADA-I supports a
wide range of neuronal growth and development using
both in vitro and in situ cell culture systems.
A tissue gap caused by deep transection of the optic tract
in the hamster midbrain and injection of saline can
completely block reinnervation of the superior colliculus
(SC) by the retina even at young ages [postnatal days (P)
when the axons typically have more regenerative
potential. Saline was used, because it is the standard
irrigant for most neurosurgical procedures and is
considered to be benign in the brain. Before the use of the
SAPNS, we demonstrated substantial recovery of visual-
orienting behavior in hamsters using a peripheral nerve
optic tract bridge model. In this model, the optic tract was
completely severed at the brachium of the SC, and the
reconnection of the optic tract was accomplished with
several surgically implanted segments of sciatic nerve
taken from one of the animals’ legs. However, the use of
this model often results in leg disabilities in experimental
animals1. 
In an attempt to facilitate optic tract regeneration with
restoration of function, without additional clinical
complications, we asked whether the SAPNS could create a
permissive environment for regeneration in the damaged
tissues as a substitute for sciatic nerve grafts. We
examined both short- and long-term effects of injecting a
peptide scaffold into the wound site in both young and
adult animals using this model. Here we report that the
SAPNS not only permitted significant axonal growth
through the site of the treated lesion, partially restoring
the optic tract, but also resulted in the return of functional
vision in brachium transected experimental adult animals.
We show that use of this biological nanofiber scaffold is
an effective approach to facilitate the reconstruction of a
continuous tissue substrate after CNS injury1.
REGENERATED AXONS REVERSE BLINDNESS 
We showed that the treatment with SAPNS solution
enabled reconnection of brain tissue after acute injury that
resulted in recovery of vision. The scaffold knitted
together tissue in the mammalian CNS in both young and
adult animals. Before the SAPNS, no treatment we tried
created a permissive environment for axonal regeneration
that allowed growth through the center of a lesion. These
experiments show that, with a single SAPNS solution
treatment at the site of injury, it is possible to overcome a
major barrier to CNS regeneration in the optic tract of
hamsters1. 
Our previous work using the optic tract transection
peripheral nerve bridge model showed that a minimum
level of 42% of normal local axonal innervation density in
the target area is required for return of functional vision.
In two adult animals of the present study, one at 30- and
another at 45-day survival, there was evidence of axons in
the SC, but the innervations density reached 20% of
normal density and, in agreement with the earlier study,
failed to restore functional vision. Because the SAPNS is
highly hydrated, with 99% water content, it can fill an
irregular void before assembly and then assemble to form
the molecular nanofiber scaffold. This in situ self-
assembly property may be critical, because most other
materials do not conform to irregular voids created by
injuries. This kind of intimate contact between nanofibers
and the extracellular matrix may be critical to facilitate
cell-scaffold interaction, thus encouraging brain injury
healing1. 
We have shown that axons grew across the lesion site in
100% of the SAPNS-treated cases in both young and old
animals, and that visually guided behavior was found in
75% of the adult animals receiving the SAPNS. The
percentage would have been higher, except the vascular
injury during surgery caused the SC to almost completely
disappear in two adults. When the behavioral testing
results for orienting are examined, there is a trend of
improved responses as the testing progresses over time. 
The SAPNS is nontoxic, and the degradation products, 
L-amino acids, could potentially be used by nearby cells
for growth and repair. Coupled with the ability of the
material to facilitate neural tissue reconstruction within
the first 24 hours after injury, peptide scaffolds offer a
promising alternative to autografts of peripheral nerve or
other tissues for recovery from CNS injury. We also found,
in each case where the peptide scaffold solution was
injected in the brain, that there was no apparent
inflammatory response as seen in the control cases, which
resulted in considerable cell death and a tissue gap1. 
The SAPNS is nontoxic, and the degradation products, 
L-amino acids, could potentially be used by nearby cells
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for growth and repair. Coupled with the ability of the
material to facilitate neural tissue reconstruction within
the first 24 hours after injury, peptide scaffolds offer a
promising alternative to autografts of peripheral nerve or
other tissues for recovery from CNS injury.
We also found, in each case where the peptide scaffold
solution was injected in the brain, that there was no
apparent inflammatory response as seen in the control
cases, which resulted in considerable cell death and a
tissue gap1. 
It is not clear exactly how the SAPNS promotes the 
closing of neural tissue gaps enabling axon regrowth. 
It is likely that it interacts at the nanoscale level with the
extracellular matrix on both sides of the lesion. It is
plausible that the SAPNS may promote cell migration into
the lesion area, which creates a growth-permissive
environment enabling axons to grow through the treated
lesion site. It is also possible that it brings the two sides
of the lesion together through a contractile process. By
using the designed SAPNS solution, we have facilitated
CNS healing and have overcome some of the barriers to
CNS axon regeneration previously thought to be nearly
impenetrable. This allowed functional recovery
demonstrated by a return of lost vision1. 
Using nanobiomedical technology and molecular self-
assembly to repair brain structures opens up a new field
and a new source of hope for efficacious treatment of CNS
trauma. This successful outcome gives us a glimpse of
what reconstructive brain surgery may hold for the future.
USING NANOTECHNOLOGY TO STOP BLEEDING
IN LESS THAN 15 SECONDS
Through the ages doctors have found ways to achieve
hemostasis, beginning with the simple act of applying
pressure, then cauterization, ligation, and clinically
induced vasoconstriction, but nanotechnology brings new
possibilities for changes in medical technology. Here we
present a novel method to stop bleeding using materials
that self-assemble at the nanoscale when applied to a
wound. This method results in the formation of a
nanofiber barrier that stops bleeding in any wet ionic
environment in the body; furthermore, the material is
broken down into natural l-amino acids that can be used
by the surrounding tissue for repair. 
Currently there are three basic categories of hemostatic
agents or procedures: chemical, thermal, and mechanical.
Chemical agents are those that change the clotting activity
of the blood or act as vasoconstrictors, such as
thromboxane A2, which causes vessels to contract thus
reducing blood flow and promoting clotting. Thermal
devices commonly involve cauterization using electrodes,
lasers, or heat. There are also agents that react
exothermically upon application that may create an effect
similar to a standard two probe cautery device. Mechanical
methods use pressure or ligature to slow the blood flow. 
A combination therapy might use both chemical and
mechanical means to produce a hemostat that adsorbs
fluid and swells, producing pressure to slow the blood
flow and allow clotting, or it may involve the introduction
of fibrinogen, thrombin, and calcium to produce fibrin
glue, which acts as an artificial clot.
LIMITATIONS OF CURRENT HEMOSTATIC AGENTS
There are five major issues related to the limitations and
applicability of many of these hemostatic agents. First,
some of the materials are solid, such as powder
formulations, and are not able to flow into the area of
injury to bring about their hemostatic effects, second,
some liquid agents, such as cyanoacrylates, require a dry
environment to be effective; third, some materials can
create an immune response resulting in the death of
adjacent cells, placing additional stress on the body that
can prolong or prevent healing; fourth, some agents have
a short shelf-life and very specific handling requirements;
and finally, many currently used hemostats are difficult to
use in uncontrolled environments. Moreover, if a therapy
uses swelling as part of its hemostatic action, then extra
care must be taken to ensure that the local blood supply
is not reduced or stopped, which could cause additional
tissue damage or even death. This is particularly crucial
when using expanding foams. Many hemostatic agents
must be prepared just before use because of their short
shelf-life. Surgical instruments, such as cauterization
devices, clamps and clips, must be used by a skilled
individual in a controlled environment.
We wanted to know if the rapid hemostasis that we had
observed in our nerve regeneration experiments was
tissue specific or would also work in other tissues. The
seven experiments we designed and performed
demonstrate that in less than 15 seconds complete
hemostasis can be achieved after (1) a transection of a
blood vessel leading to the superior sagittal sinus in both
hamsters and rats, (2) a spinal cord cut, (3) a femoral
artery cut, (4) a sagittal transection of the left lateral liver
lobe, (5) a transverse transection of the left lateral liver
lobe including a cut in a primary branch of the portal vein,
(6) a 4-mm liver punch biopsy, and (7) multiple 4-mm
skin punch biopsies on nude mice2. 
RAPID HEMOSTASIS ACHIEVED IN 
MULTIPLE TISSUES
Our study demonstrates that hemostasis can be achieved
in less than 15 seconds in multiple tissues as well as a
variety of different wounds. This is the first time that
nanotechnology has been used to stop bleeding in a
surgical setting for animal models and seems to
demonstrate a new class of hemostatic agent that does
not rely on heat, pressure, platelet activation, adhesion, or
desiccation to stop bleeding. Nanohemostat-1 (NHS-1)
and NHS-2 are synthetic, biodegradable and do not
contain any blood products, collagens, or biological
contaminants that may be present in human- or animal-
derived hemostatic agents such as fibrin glue. They can be
applied directly onto, or into, a wound without the
280 | North American Neuro-Ophthalmology Society
concern that the material may expand, thus reducing the
risk of secondary tissue damage as well as the problems
caused by constricted blood flow2. 
In our previous brain studies we looked for evidence of
the production of prion-like substances or fibril tangles in
animals that had the material implanted in their brain for
as long as 6 months but found none. Furthermore, the
breakdown products of NHS-1 are amino acids, which can
be used by the body as tissue building blocks for the
repair of the injury. Independent third-party testing of the
material found no pyrogenicity, which has been found
with some other hemostatic agents, and no systemic
coagulation or other safety issues in animals1. 
The exact mechanism for the hemostasis reported here is
not fully understood, but we know that the hemostasis is
not explainable by clotting, or platelet aggregation, or by
gelation kinetics. One would think that a stiffer gel would
be more effective for higher pressure bleeders; however,
we found the opposite to be true. 
The ability to speedily achieve hemostasis will radically
reduce the quantity of blood needed during surgery of the
future. As much as 50% of surgical time can be spent
packing wounds to reduce or control bleeding. The NHS
solutions may represent a step change in technology and
could revolutionize bleeding control during surgery and
trauma; however, they still require clinical testing before
they can be used in humans.
CME ANSWERS
1. It depends on the sequence. Some sequences are
vasoactive and some are immunogenic.
2. Polymerized materials will form covalent bonds and
can be very difficult to breakdown in the body. They
can also form hard barriers that will not allow for
migration of cells. Yes, some of them can polymerize
and form very stable bonds. 
3. pH can cause signalling of receptors and activation of
the PAF system which can cause diffuse pain. The
distance the pH acts is usually in the nanometer range;
however, the effects can spread to centimetres. The
change in pH can also cause materials to assemble
differently.
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